The interaction of McN-A-343 with muscarine receptors in cardiac and smooth muscle.
The interaction of the muscarine receptor partial agonist (4-m-chlorophenylcarbamoyloxy)-2-butynyltrimethylammonium chloride (McN-A-343) was investigated at muscarine receptors in the atria and taenia caeci of the guinea-pig to compare its interaction at the muscarine M2 receptor in the two tissues. In the smooth muscle, the muscarine M3 receptor subtype is responsible for the contractile response but the major subtype detected in binding or antibody experiments is the M2 subtype. In guinea pig atria the dissociation constant of McN-A-343 at muscarine receptors was 15.2 microM determined in functional experiments on left atria in McEwen's solution or 14.8 microM in binding experiments with [3H]-(-)-quinuclidinyl benzilate ([3H]QNB) in the same medium containing 5'-guanylylimododiphosphate (50 microM). In the taenia caeci, the dissociation constant estimated for McN-A-343 at the M3 receptor from functional experiments based on the contractile response to the agonist in McEwen's solution was 4.6 microM. This value was similar to the dissociation constant (6.2 microM) estimated from binding studies versus [3H]QNB conducted in the same medium although studies with 11-[[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H- pyrido[2,3-b][1,4]benzodiazepine 6-one (AF-DX 116) versus [3H]-(-)-N-methylscopolamine suggested that 70% of the receptors were the M2 subtype. The presence of the M2 subtype in the taenia caeci was also confirmed by the ability of oxotremorine to inhibit the increase in cAMP produced by isoprenaline (10 microM) since apparent pKB values for AF-DX 116 and hexahydrosiladiphenidol were 6.95 and 6.75, respectively. McN-A-343 (100 microM) failed to inhibit the response to isoprenaline and did not antagonize the inhibitory response to oxotremorine. It is concluded that the apparent affinity of McN-A-343 for muscarine M2 receptors in the atria and the taenia caeci differs and a number of explanations are discussed.
Elnatan
A
A
School of Pharmacology, Victorian College of Pharmacy (Monash University), Parkville, Australia.
Mitchelson
F
F
D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride / Q000494:pharmacology*; D000818:Animals; D001667:Binding, Competitive; D002432:Cecum / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D006168:Guinea Pigs; D006325:Heart Atria; D018727:Muscarinic Antagonists; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism*; D011813:Quinuclidinyl Benzilate / Q000494:pharmacology; D011976:Receptors, Muscarinic / Q000187:drug effects*; D014316:Tritium
D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic; D014316:Tritium; D008455:(4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride; D011813:Quinuclidinyl Benzilate; D000242:Cyclic AMP